542 related articles for article (PubMed ID: 26730496)
1. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
2. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
Furtek SL; Matheson CJ; Backos DS; Reigan P
Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
Yu W; Xiao H; Lin J; Li C
J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.
Page BD; Croucher DC; Li ZH; Haftchenary S; Jimenez-Zepeda VH; Atkinson J; Spagnuolo PA; Wong YL; Colaguori R; Lewis AM; Schimmer AD; Trudel S; Gunning PT
J Med Chem; 2013 Sep; 56(18):7190-200. PubMed ID: 23968501
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.
Haftchenary S; Avadisian M; Gunning PT
Anticancer Drugs; 2011 Feb; 22(2):115-27. PubMed ID: 21063201
[TBL] [Abstract][Full Text] [Related]
9. STAT 3 as a target for cancer drug discovery.
Costantino L; Barlocco D
Curr Med Chem; 2008; 15(9):834-43. PubMed ID: 18473793
[TBL] [Abstract][Full Text] [Related]
10. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.
Dong J; Cheng XD; Zhang WD; Qin JJ
J Med Chem; 2021 Jul; 64(13):8884-8915. PubMed ID: 34170703
[TBL] [Abstract][Full Text] [Related]
11. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening.
Zhang M; Zhu W; Ding N; Zhang W; Li Y
Bioorg Med Chem Lett; 2013 Apr; 23(7):2225-9. PubMed ID: 23434226
[TBL] [Abstract][Full Text] [Related]
13. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.
Siddiquee K; Zhang S; Guida WC; Blaskovich MA; Greedy B; Lawrence HR; Yip ML; Jove R; McLaughlin MM; Lawrence NJ; Sebti SM; Turkson J
Proc Natl Acad Sci U S A; 2007 May; 104(18):7391-6. PubMed ID: 17463090
[TBL] [Abstract][Full Text] [Related]
14. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
Huang Q; Zhong Y; Li B; Ouyang S; Deng L; Mo J; Shi S; Lv N; Wu R; Liu P; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2021 Oct; 221():113525. PubMed ID: 34000483
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening.
Zhang M; Zhu W; Li Y
Eur J Med Chem; 2013 Apr; 62():301-10. PubMed ID: 23376248
[TBL] [Abstract][Full Text] [Related]
16. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
[TBL] [Abstract][Full Text] [Related]
17. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
Kolosenko I; Yu Y; Busker S; Dyczynski M; Liu J; Haraldsson M; Palm Apergi C; Helleday T; Tamm KP; Page BDG; Grander D
PLoS One; 2017; 12(6):e0178844. PubMed ID: 28636670
[TBL] [Abstract][Full Text] [Related]
19. STAT3-Interacting Proteins as Modulators of Transcription Factor Function: Implications to Targeted Cancer Therapy.
Yeh JE; Frank DA
ChemMedChem; 2016 Apr; 11(8):795-801. PubMed ID: 26662504
[TBL] [Abstract][Full Text] [Related]
20. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion.
Huang W; Dong Z; Wang F; Peng H; Liu JY; Zhang JT
ACS Chem Biol; 2014 May; 9(5):1188-96. PubMed ID: 24661007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]